Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127534641 | 12753464 | 1 | I | 20160902 | 20160916 | 20160916 | PER | US-PFIZER INC-2016420210 | PFIZER | 69.00 | YR | F | Y | 0.00000 | 20160916 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127534641 | 12753464 | 1 | PS | IBRANCE | PALBOCICLIB | 1 | 75 MG, CYCLIC (21 DAY CYCLE; 28 DAY SUPPLY) | U | 207103 | 75 | MG | CAPSULE | |||||||
| 127534641 | 12753464 | 2 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 125 MG, DAILY | U | 207103 | 125 | MG | CAPSULE | ||||||
| 127534641 | 12753464 | 3 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 75 MG, DAILY (AS DIRECTED) | U | 207103 | 75 | MG | CAPSULE | ||||||
| 127534641 | 12753464 | 4 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 75 MG, DAILY | U | 207103 | 75 | MG | CAPSULE | ||||||
| 127534641 | 12753464 | 5 | SS | FEMARA | LETROZOLE | 1 | Oral | 2.5 MG, DAILY (1 TABLET DAILY) | U | 0 | 2.5 | MG | TABLET | ||||||
| 127534641 | 12753464 | 6 | SS | FEMARA | LETROZOLE | 1 | U | 0 | TABLET | ||||||||||
| 127534641 | 12753464 | 7 | SS | FEMARA | LETROZOLE | 1 | U | 0 | TABLET | ||||||||||
| 127534641 | 12753464 | 8 | SS | FEMARA | LETROZOLE | 1 | U | 0 | TABLET | ||||||||||
| 127534641 | 12753464 | 9 | SS | XGEVA | DENOSUMAB | 1 | UNK UNK, MONTHLY | Y | 0 | SOLUTION FOR INJECTION | /month | ||||||||
| 127534641 | 12753464 | 10 | SS | XGEVA | DENOSUMAB | 1 | Subcutaneous | 120 MG, SINGLE (OF 120MG/1.70 ML) | Y | 0 | 120 | MG | SOLUTION FOR INJECTION | ||||||
| 127534641 | 12753464 | 11 | SS | XGEVA | DENOSUMAB | 1 | Y | 0 | SOLUTION FOR INJECTION | ||||||||||
| 127534641 | 12753464 | 12 | SS | XGEVA | DENOSUMAB | 1 | Y | 0 | SOLUTION FOR INJECTION | ||||||||||
| 127534641 | 12753464 | 13 | C | CELEXA | CITALOPRAM HYDROBROMIDE | 1 | UNK | 0 | |||||||||||
| 127534641 | 12753464 | 14 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | UNK UNK, DAILY | 0 | TABLET | |||||||||
| 127534641 | 12753464 | 15 | C | CANNABIS SATIVA OIL | CANNABIS SATIVA SUBSP. INDICA TOP | 1 | UNK | 0 | |||||||||||
| 127534641 | 12753464 | 16 | C | VITAMIN B6 | PYRIDOXINE HYDROCHLORIDE | 1 | UNK UNK, DAILY | 0 | TABLET | ||||||||||
| 127534641 | 12753464 | 17 | C | VITAMIN C | ASCORBIC ACID | 1 | 500 MG, DAILY | 0 | 500 | MG | TABLET | ||||||||
| 127534641 | 12753464 | 18 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 4000 IU, DAILY | 0 | 4000 | IU | CAPSULE | ||||||||
| 127534641 | 12753464 | 19 | C | ESCITALOPRAM OXALATE. | ESCITALOPRAM OXALATE | 1 | Oral | 20 MG, DAILY | 0 | 20 | MG | TABLET | |||||||
| 127534641 | 12753464 | 20 | C | ESCITALOPRAM OXALATE. | ESCITALOPRAM OXALATE | 1 | Oral | 20 MG, DAILY | 0 | 20 | MG | TABLET | |||||||
| 127534641 | 12753464 | 21 | C | HEPARIN | HEPARIN SODIUM | 1 | Intravenous (not otherwise specified) | 100 IU/ML, SINGLE (5 ML) | 0 | SOLUTION FOR INJECTION | |||||||||
| 127534641 | 12753464 | 22 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 0.5 MG, UNK (AS DIRECTED) | 0 | .5 | MG | TABLET | |||||||
| 127534641 | 12753464 | 23 | C | ONDANSETRON HCL | ONDANSETRON HYDROCHLORIDE | 1 | Oral | 8 MG, AS NEEDED (TID) | 0 | 8 | MG | TABLET | |||||||
| 127534641 | 12753464 | 24 | C | ONDANSETRON HCL | ONDANSETRON HYDROCHLORIDE | 1 | Oral | 8 MG, AS NEEDED (BID) | 0 | 8 | MG | TABLET | |||||||
| 127534641 | 12753464 | 25 | C | COENZYME Q10 | UBIDECARENONE | 1 | 100 MG, DAILY | 0 | 100 | MG | TABLET | ||||||||
| 127534641 | 12753464 | 26 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Oral | 500 MG, 1X/DAY | 0 | 500 | MG | TABLET | QD | ||||||
| 127534641 | 12753464 | 27 | C | ALTEPLASE | ALTEPLASE | 1 | Intravenous (not otherwise specified) | UNK, SINGLE (2 MG (OF 1MG/ML) | 0 | SOLUTION FOR INJECTION | |||||||||
| 127534641 | 12753464 | 28 | C | AMOXICILLIN + CLAV. POTASSIUM | 2 | Oral | 1 DF, 2X/DAY (AMOXICILLIN TRIHYDRATE-875MG/CLAVULANATE POTASSIUM-125MG) (1 TAB BID FOR 7 DAYS) | 0 | 1 | DF | TABLET | BID | |||||||
| 127534641 | 12753464 | 29 | C | ZOLEDRONIC ACID | ZOLEDRONIC ACID | 1 | UNK | 0 | |||||||||||
| 127534641 | 12753464 | 30 | C | ANASTROZOLE. | ANASTROZOLE | 1 | Oral | UNK UNK, DAILY | 0 | TABLET | |||||||||
| 127534641 | 12753464 | 31 | C | BENAZEPRIL HCL | BENAZEPRIL HYDROCHLORIDE | 1 | Oral | UNK, DAILY | 0 | TABLET | |||||||||
| 127534641 | 12753464 | 32 | C | PRAVASTATIN SODIUM. | PRAVASTATIN SODIUM | 1 | Oral | UNK UNK, DAILY | 0 | TABLET | |||||||||
| 127534641 | 12753464 | 33 | C | SILVADENE | SILVER SULFADIAZINE | 1 | Topical | 1 %, UNK (AS DIRECTED) | 0 | 1 | PCT | CREAM | |||||||
| 127534641 | 12753464 | 34 | C | TAMOXIFEN CITRATE. | TAMOXIFEN CITRATE | 1 | Oral | 20 MG, DAILY | 0 | 20 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127534641 | 12753464 | 1 | Breast cancer metastatic |
| 127534641 | 12753464 | 2 | Adrenal gland cancer metastatic |
| 127534641 | 12753464 | 3 | Metastases to lung |
| 127534641 | 12753464 | 4 | Metastases to bone |
| 127534641 | 12753464 | 5 | Breast cancer metastatic |
| 127534641 | 12753464 | 6 | Adrenal gland cancer metastatic |
| 127534641 | 12753464 | 7 | Metastases to lung |
| 127534641 | 12753464 | 8 | Metastases to bone |
| 127534641 | 12753464 | 9 | Breast cancer metastatic |
| 127534641 | 12753464 | 10 | Adrenal gland cancer metastatic |
| 127534641 | 12753464 | 11 | Metastases to lung |
| 127534641 | 12753464 | 12 | Metastases to bone |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127534641 | 12753464 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127534641 | 12753464 | Blood pressure abnormal | |
| 127534641 | 12753464 | Lymphoedema | |
| 127534641 | 12753464 | Pain in extremity | |
| 127534641 | 12753464 | Post procedural oedema | |
| 127534641 | 12753464 | Pyrexia | |
| 127534641 | 12753464 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127534641 | 12753464 | 2 | 20150814 | 0 | ||
| 127534641 | 12753464 | 3 | 20150911 | 0 | ||
| 127534641 | 12753464 | 5 | 20150814 | 0 | ||
| 127534641 | 12753464 | 10 | 20151106 | 20160729 | 0 | |
| 127534641 | 12753464 | 14 | 20140425 | 20160729 | 0 | |
| 127534641 | 12753464 | 16 | 20140425 | 0 | ||
| 127534641 | 12753464 | 17 | 20140425 | 0 | ||
| 127534641 | 12753464 | 18 | 20140425 | 0 | ||
| 127534641 | 12753464 | 19 | 20140425 | 0 | ||
| 127534641 | 12753464 | 20 | 20151023 | 0 | ||
| 127534641 | 12753464 | 21 | 20160108 | 0 | ||
| 127534641 | 12753464 | 22 | 20151207 | 0 | ||
| 127534641 | 12753464 | 23 | 20150814 | 0 | ||
| 127534641 | 12753464 | 24 | 20150814 | 0 | ||
| 127534641 | 12753464 | 25 | 20140425 | 0 | ||
| 127534641 | 12753464 | 26 | 20151009 | 20151009 | 0 | |
| 127534641 | 12753464 | 27 | 20160205 | 20160205 | 0 | |
| 127534641 | 12753464 | 28 | 20151009 | 20151030 | 0 | |
| 127534641 | 12753464 | 29 | 20151009 | 0 | ||
| 127534641 | 12753464 | 30 | 20140904 | 20150805 | 0 | |
| 127534641 | 12753464 | 31 | 20140425 | 20160729 | 0 | |
| 127534641 | 12753464 | 32 | 20140425 | 20150805 | 0 | |
| 127534641 | 12753464 | 33 | 20140715 | 20140904 | 0 | |
| 127534641 | 12753464 | 34 | 20140904 | 20140905 | 0 |